IBRUTINIB / IBR501 kapsel Eesti - eesti - Ravimiamet

ibrutinib / ibr501 kapsel

janssen biotech inc. - ibrutiniib - kapsel - 140mg 92tk; 140mg 90tk; 140mg 120tk

Brukinsa Euroopa Liit - eesti - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastilised ained - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Jaypirca Euroopa Liit - eesti - EMA (European Medicines Agency)

jaypirca

eli lilly nederland b.v. - pirtobrutinib - lümfoom, mantle-cell - protein kinase inhibiitorid - treatment of mantle cell lymphoma (mcl).

Imbruvica Euroopa Liit - eesti - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

TROXERUTIN SOPHARMA geel Eesti - eesti - Ravimiamet

troxerutin sopharma geel

sopharma ad - trokserutiin - geel - 20mg 1g 40g 1tk

IBR502 kapsel Eesti - eesti - Ravimiamet

ibr502 kapsel

janssen-cilag - ibrutiniib - kapsel - 140mg 90tk; 140mg 120tk

Paxlovid Euroopa Liit - eesti - EMA (European Medicines Agency)

paxlovid

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

FLUNOC kõvakapsel Eesti - eesti - Ravimiamet

flunoc kõvakapsel

sandoz pharmaceuticals d.d. - flukonasool - kõvakapsel - 50mg 30tk; 50mg 20tk; 50mg 42tk; 50mg 10tk; 50mg 100tk; 50mg 3tk; 50mg 14tk; 50mg 7tk; 50mg 50tk; 50mg 98tk; 50mg 28tk

FLUNOC kõvakapsel Eesti - eesti - Ravimiamet

flunoc kõvakapsel

sandoz pharmaceuticals d.d. - flukonasool - kõvakapsel - 150mg 1tk; 150mg 4tk; 150mg 2tk; 150mg 6tk

FLUCONAZOLE VITABALANS tablett Eesti - eesti - Ravimiamet

fluconazole vitabalans tablett

vitabalans oy - flukonasool - tablett - 150mg 6tk; 150mg 2tk; 150mg 30tk; 150mg 4tk; 150mg 12tk; 150mg 1tk